Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Augustin

Showing results (381-390 of 491) with videos related to

Pageof 50
Sort By:
Frontiers in Medicine|May 22, 2023
Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measureRachael Pattinson, Nirohshah Trialonis-Suthakharan, Rachael M Hewitt, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Acta Dermato-Venereologica|March 6, 2025
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HSNatalia Kirsten, Matthias Augustin, Christine Blome, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|February 17, 2021
Assessing the quality of life of people with chronic wounds by using the cross-culturally valid and revised Wound-QoL questionnaireCatharina C von Stülpnagel, Neuza da Silva, Matthias Augustin, et al.
Healthcare (Basel, Switzerland)|May 14, 2025
Communication and Therapy Planning for Patients of Reproductive Age Under Immunomodulatory Treatments for Psoriasis or Psoriatic Arthritis-Survey of the German National Psoriasis Registry PsoBestBrigitte Stephan, Christina Sorbe, Birgit-Christiane Zyriax, et al.
Plos One|May 26, 2018
Willingness to pay for a cure of low-risk melanoma patients in GermanyMatthias Augustin, Christine Blome, Andrea Forschner, et al.
Journal of the American Academy of Dermatology|October 4, 2016
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasisSteven R Feldman, Diamant Thaçi, Melinda Gooderham, et al.
Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.
Journal of Clinical Medicine|July 13, 2024
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBestBrigitte Stephan, Stephan Jeff Rustenbach, Nesrine Ben-Anaya, et al.
Dermatology and Therapy|August 8, 2020
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, et al.
Pageof 50

Showing results (381-390 of 491) with videos related to

Sort By:
Pageof 50
Frontiers in Medicine|May 22, 2023
Evidence of the content validity, acceptability, and feasibility of a new Patient-Reported Impact of Dermatological Diseases measureRachael Pattinson, Nirohshah Trialonis-Suthakharan, Rachael M Hewitt, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Acta Dermato-Venereologica|March 6, 2025
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HSNatalia Kirsten, Matthias Augustin, Christine Blome, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|February 17, 2021
Assessing the quality of life of people with chronic wounds by using the cross-culturally valid and revised Wound-QoL questionnaireCatharina C von Stülpnagel, Neuza da Silva, Matthias Augustin, et al.
Healthcare (Basel, Switzerland)|May 14, 2025
Communication and Therapy Planning for Patients of Reproductive Age Under Immunomodulatory Treatments for Psoriasis or Psoriatic Arthritis-Survey of the German National Psoriasis Registry PsoBestBrigitte Stephan, Christina Sorbe, Birgit-Christiane Zyriax, et al.
Plos One|May 26, 2018
Willingness to pay for a cure of low-risk melanoma patients in GermanyMatthias Augustin, Christine Blome, Andrea Forschner, et al.
Journal of the American Academy of Dermatology|October 4, 2016
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasisSteven R Feldman, Diamant Thaçi, Melinda Gooderham, et al.
Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.
Journal of Clinical Medicine|July 13, 2024
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBestBrigitte Stephan, Stephan Jeff Rustenbach, Nesrine Ben-Anaya, et al.
Dermatology and Therapy|August 8, 2020
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)Jean-Philippe Lacour, Anthony Bewley, Edward Hammond, et al.
Pageof 50